Primary treatment for rhabdomyosarcoma in Israel includes a multimodal approach combining surgical tumor removal, systemic chemotherapy, and precision radiation therapy. Israeli oncology centers utilize advanced molecular subtyping and genomic sequencing to personalize these treatments within JCI-accredited facilities.
- Surgical intervention: Surgeons aim for complete resection while prioritizing limb preservation and functional outcomes.
- Chemotherapy protocols: Mandatory systemic treatments often use the IVA or VAC drug combination regimens.
- Precision radiation: Specialized centers use 3D navigation and dosimetry to target tumors accurately.
- Supportive therapies: Treatment plans may include bone marrow transplantation and CAR-T or TIL immunotherapies.
Bookimed Expert Insight: Israeli oncology centers like Sourasky and Sheba specialize in complex bone and soft tissue cases. Dr. Ofer Merimsky and Dr. Boaz Liberman demonstrate that top specialists often lead national sarcoma units. This concentration of expertise allows for survival rates as high as 90% in certain oncology cases. Patients benefit most when specific pediatric hemato-oncologists, such as Dr. Iris Kventsel, manage the integration of surgery with advanced biological research.
Patient Consensus: Patients emphasize that starting fertility preservation before beginning intensive chemotherapy is a vital but often overlooked step. Families note the importance of achieving clean surgical margins to reduce recurrence risks during the year-long treatment journey.